Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event (Details)

Subsequent Event (Details) - USD ($)
1 Months Ended 3 Months Ended
May 15, 2020
May 04, 2020
Apr. 28, 2020
Apr. 23, 2020
Apr. 17, 2020
Apr. 02, 2020
Apr. 01, 2020
May 11, 2020
Apr. 30, 2020
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Subsequent Event (Textual)                        
Stock-based professional fees                   $ (15,000) $ (49,646)  
Derivative liability                   $ 1,310,654   $ 890,410
Convertible debt [Member]                        
Subsequent Event (Textual)                        
Warrants to purchase of common shares                   144,375    
Net proceeds                   $ 44,187    
Exercise price                   $ 0.10    
Derivative liability                   $ 89,976    
Operations initial derivative expense                   35,789    
Fair value of warrants                   $ 5,813    
Subsequent Event [Member]                        
Subsequent Event (Textual)                        
Number of aggregate common shares         203,125       2,500,000      
Accrued interest                 $ 10,470      
Fees                 500      
Convertible debt                 $ 44,530      
Conversion of deferred stock         $ 16,250              
Aggregate principal amount     $ 280,000                  
Note converted, description             The Company entered into two one-year advisory board agreements with two individuals for services to be rendered on the Company’s medical advisory board. In connection with these advisory board agreements, the Company issued an aggregate of 500,000 restricted common shares of the Company to these advisory board members. These shares vest on April 1, 2021. These shares were valued at $20,000, or $0.04 per common share, based on contemporaneous common share sales by the Company. In connection with this consulting agreement Company shall record stock-based consulting fees over the vesting period. The Company closed a subscription agreement with an accredited investor (the "Investor") whereby the Investor purchased 7,000,000 unregistered shares of the Company's common stock for proceeds of $161,000, or $0.023 per share.        
Description of promissory note     The Company entered into a Paycheck Protection Program Promissory Note (the "PPP Note") with respect to a loan of $156,200 (the "PPP Loan") from Comerica Bank. The PPP Loan was obtained pursuant to the Paycheck Protection Program (the "PPP") of the Coronavirus Aid, Relief, and Economic Security Act (the "CARES act") administered by the U.S. Small Business Administration ("SBA"). The PPP Loan matures on April 28, 2022 and bears interest at a rate of 1.00% per annum. The PPP Loan is payable in 18 equal monthly payments of approximately $8,900 commencing November 1, 2020. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. The Company may apply to have the loan forgiven pursuant to the terms of the PPP if certain criteria are met.                  
Subsequent Event [Member] | Convertible debt [Member]                        
Subsequent Event (Textual)                        
Aggregate principal amount       $ 57,750                
Warrants to purchase of common shares       144,375                
Net proceeds       $ 50,000                
Original issue discount       5,000                
Origination fees       $ 2,750                
Note bears interest rate       12.00%                
Due and payable date       Jan. 23, 2021                
Note converted, description       In accordance with the April 2020 and this Note, subject to the adjustments as defined in the April 2020 SPA and Note, the conversion price (the "Conversion Price") shall equal the lesser of: (i) the lowest Trading Price (as defined below) during the previous twenty-five Trading Day period ending on the latest complete Trading Day prior to the date of this Note, and (ii) the Variable Conversion Price (as defined below) (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Company). The "Variable Conversion Price" shall mean 60% multiplied by the Market Price (as defined herein) (representing a discount rate of 40%).                
Subsequent Event [Member] | Series A Preferred Stock [Member]                        
Subsequent Event (Textual)                        
Number of aggregate common shares 593,023 618,182             1,782,097      
Conversion of Stock, Shares Issued 10,000 12,000             67,406      
Accrued interest $ 200 $ 240             $ 1,348      
Preferred stock redemption value $ 10,000 $ 12,000             $ 67,406      
Restricted Stock Award Agreements [Member] | Subsequent Event [Member]                        
Subsequent Event (Textual)                        
Common stock, Par value     $ 0.04                  
Restricted common shares     6,750,000                  
Restricted common shares, valued     $ 270,000                  
Percentage of restricted shares     100.00%                  
Employment Agreement [Member] | Subsequent Event [Member]                        
Subsequent Event (Textual)                        
Common stock, Par value           $ 0.04            
Restricted common shares           200,000            
Date of grant value           $ 8,000